Female Contraception - Pipeline Review, H2 2019
Female Contraception - Pipeline Review, H2 2019
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Contraception - Pipeline Review, H2 2019, provides an overview of the Female Contraception (Women's Health) pipeline landscape.
Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices (IUDs), pills and vaginal rings, barrier methods, sterilization and natural methods. Contraception generally work by preventing sperm from reaching and fertilizing an egg (barrier and IUD methods), preventing an egg from being released every month (hormones), blocking the reproductive function (sterilization) and preventing a fertilized egg from implanting in the uterus (hormones).
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Contraception - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Female Contraception (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Female Contraception (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 5, 3, 12 and 5 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.
Female Contraception (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Contraception - Pipeline Review, H2 2019, provides an overview of the Female Contraception (Women's Health) pipeline landscape.
Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices (IUDs), pills and vaginal rings, barrier methods, sterilization and natural methods. Contraception generally work by preventing sperm from reaching and fertilizing an egg (barrier and IUD methods), preventing an egg from being released every month (hormones), blocking the reproductive function (sterilization) and preventing a fertilized egg from implanting in the uterus (hormones).
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Contraception - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Female Contraception (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Female Contraception (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 5, 3, 12 and 5 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.
Female Contraception (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Female Contraception (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Female Contraception (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Female Contraception (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Female Contraception (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Female Contraception (Women's Health)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Female Contraception (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Female Contraception (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Female Contraception - Overview
Female Contraception - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Female Contraception - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Female Contraception - Companies Involved in Therapeutics Development
Agile Therapeutics Inc
Evestra Inc
Evofem Biosciences Inc
Exeltis Pharmaceuticals Holding SL
Hervana Ltd
Hydra Biosciences Inc
Luye Pharma Group Ltd
MedinCell SA
Micron Biomedical Inc
Mithra Pharmaceuticals SA
Mucommune LLC
Orbis Biosciences Inc
Orion Biotechnology Canada Ltd
Ovastasis LLC
Teva Pharmaceutical Industries Ltd
Viramal Ltd
Yaso Therapeutics Inc
YourChoice Therapeutics Inc
Female Contraception - Drug Profiles
(dienogest + ethinylestradiol) PR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(drospirenone + estetrol) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(estradiol + segesterone acetate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(ethinyl estradiol + levonorgestrel) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(ethinylestradiol + gestodene) ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AG-200 ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AG-200 SP - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AG-890 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Amphora - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DARE-RH1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Female Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-317 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-508 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-625 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etonogestrel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etonogestrel ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HER-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levonorgestrel SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDC-WWM - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MM-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugates for Female Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PPCM - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-003296 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 1 to Agonize Progesterone Receptor for Female Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Female Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Progesterone Receptor for Female Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target Progesterone Receptor for Female Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Female and Male Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Female Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TV-46046 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Female Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Female Contraception - Dormant Projects
Female Contraception - Discontinued Products
Female Contraception - Product Development Milestones
Featured News & Press Releases
Dec 03, 2019: PDL BioPharma congratulates Evofem Biosciences on achieving major regulatory and clinical milestones with its lead product candidate Amphora
Nov 28, 2019: Medincell receives $19 million grant for Its mdc-WWM program
Nov 26, 2019: Evofem Biosciences resubmits New Drug Application to U.S. FDA for Amphora for the prevention of Pregnancy
Nov 14, 2019: Agile Therapeutics announces FDA extension of Twirla NDA review period
Oct 30, 2019: Agile Therapeutics announces favorable outcome of FDA advisory committee meeting for its investigational transdermal contraceptive patch, Twirla (AG200-15)
Oct 16, 2019: Presentation of Estelle phase III results at the 13th Meeting of the European Society of Gynecology
Aug 08, 2019: Mithra obtains crucial additional Estelle patent in Japan
Aug 05, 2019: Evofem Biosciences reports additional data from phase 3 ampower study of amphora for hormone-free birth control
Jul 23, 2019: Jubilant Cadista Pharmaceuticals issues voluntary nationwide recall of Drospirenone and Ethinyl Estradiol Tablets, USP, due to out-of-specification dissolution test results
Jul 18, 2019: Agile Therapeutics appoints chief financial officer
Jun 28, 2019: Agile Therapeutics presents on AG20015 at Women’s Health 2019
Jun 24, 2019: Agile Therapeutics announces FDA Advisory Committee Meeting for its investigational transdermal low-dose contraceptive patch, Twirla (AG200-15)
May 22, 2019: Agile Therapeutics announces FDA acceptance of the NDA resubmission of Twirla
May 17, 2019: Agile Therapeutics resubmits New Drug Application (NDA) for its present new dtransdermal low-dose contraceptive patch, Twirla
May 03, 2019: Agile Therapeutics to present combined safety data from three phase 3 studies at the 2019 ACOG Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Female Contraception - Overview
Female Contraception - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Female Contraception - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Female Contraception - Companies Involved in Therapeutics Development
Agile Therapeutics Inc
Evestra Inc
Evofem Biosciences Inc
Exeltis Pharmaceuticals Holding SL
Hervana Ltd
Hydra Biosciences Inc
Luye Pharma Group Ltd
MedinCell SA
Micron Biomedical Inc
Mithra Pharmaceuticals SA
Mucommune LLC
Orbis Biosciences Inc
Orion Biotechnology Canada Ltd
Ovastasis LLC
Teva Pharmaceutical Industries Ltd
Viramal Ltd
Yaso Therapeutics Inc
YourChoice Therapeutics Inc
Female Contraception - Drug Profiles
(dienogest + ethinylestradiol) PR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(drospirenone + estetrol) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(estradiol + segesterone acetate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(ethinyl estradiol + levonorgestrel) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(ethinylestradiol + gestodene) ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AG-200 ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AG-200 SP - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AG-890 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Amphora - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DARE-RH1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Female Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-317 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-508 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-625 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etonogestrel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etonogestrel ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HER-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levonorgestrel SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDC-WWM - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MM-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugates for Female Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PPCM - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-003296 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 1 to Agonize Progesterone Receptor for Female Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Female Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Progesterone Receptor for Female Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target Progesterone Receptor for Female Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Female and Male Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Female Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TV-46046 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Female Contraception - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Female Contraception - Dormant Projects
Female Contraception - Discontinued Products
Female Contraception - Product Development Milestones
Featured News & Press Releases
Dec 03, 2019: PDL BioPharma congratulates Evofem Biosciences on achieving major regulatory and clinical milestones with its lead product candidate Amphora
Nov 28, 2019: Medincell receives $19 million grant for Its mdc-WWM program
Nov 26, 2019: Evofem Biosciences resubmits New Drug Application to U.S. FDA for Amphora for the prevention of Pregnancy
Nov 14, 2019: Agile Therapeutics announces FDA extension of Twirla NDA review period
Oct 30, 2019: Agile Therapeutics announces favorable outcome of FDA advisory committee meeting for its investigational transdermal contraceptive patch, Twirla (AG200-15)
Oct 16, 2019: Presentation of Estelle phase III results at the 13th Meeting of the European Society of Gynecology
Aug 08, 2019: Mithra obtains crucial additional Estelle patent in Japan
Aug 05, 2019: Evofem Biosciences reports additional data from phase 3 ampower study of amphora for hormone-free birth control
Jul 23, 2019: Jubilant Cadista Pharmaceuticals issues voluntary nationwide recall of Drospirenone and Ethinyl Estradiol Tablets, USP, due to out-of-specification dissolution test results
Jul 18, 2019: Agile Therapeutics appoints chief financial officer
Jun 28, 2019: Agile Therapeutics presents on AG20015 at Women’s Health 2019
Jun 24, 2019: Agile Therapeutics announces FDA Advisory Committee Meeting for its investigational transdermal low-dose contraceptive patch, Twirla (AG200-15)
May 22, 2019: Agile Therapeutics announces FDA acceptance of the NDA resubmission of Twirla
May 17, 2019: Agile Therapeutics resubmits New Drug Application (NDA) for its present new dtransdermal low-dose contraceptive patch, Twirla
May 03, 2019: Agile Therapeutics to present combined safety data from three phase 3 studies at the 2019 ACOG Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Female Contraception, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Female Contraception - Pipeline by Agile Therapeutics Inc, H2 2019
Female Contraception - Pipeline by Evestra Inc, H2 2019
Female Contraception - Pipeline by Evofem Biosciences Inc, H2 2019
Female Contraception - Pipeline by Exeltis Pharmaceuticals Holding SL, H2 2019
Female Contraception - Pipeline by Hervana Ltd, H2 2019
Female Contraception - Pipeline by Hydra Biosciences Inc, H2 2019
Female Contraception - Pipeline by Luye Pharma Group Ltd, H2 2019
Female Contraception - Pipeline by MedinCell SA, H2 2019
Female Contraception - Pipeline by Micron Biomedical Inc, H2 2019
Female Contraception - Pipeline by Mithra Pharmaceuticals SA, H2 2019
Female Contraception - Pipeline by Mucommune LLC, H2 2019
Female Contraception - Pipeline by Orbis Biosciences Inc, H2 2019
Female Contraception - Pipeline by Orion Biotechnology Canada Ltd, H2 2019
Female Contraception - Pipeline by Ovastasis LLC, H2 2019
Female Contraception - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2019
Female Contraception - Pipeline by Viramal Ltd, H2 2019
Female Contraception - Pipeline by Yaso Therapeutics Inc, H2 2019
Female Contraception - Pipeline by YourChoice Therapeutics Inc, H2 2019
Female Contraception - Dormant Projects, H2 2019
Female Contraception - Dormant Projects, H2 2019 (Contd..1), H2 2019
Female Contraception - Discontinued Products, H2 2019
Number of Products under Development for Female Contraception, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Female Contraception - Pipeline by Agile Therapeutics Inc, H2 2019
Female Contraception - Pipeline by Evestra Inc, H2 2019
Female Contraception - Pipeline by Evofem Biosciences Inc, H2 2019
Female Contraception - Pipeline by Exeltis Pharmaceuticals Holding SL, H2 2019
Female Contraception - Pipeline by Hervana Ltd, H2 2019
Female Contraception - Pipeline by Hydra Biosciences Inc, H2 2019
Female Contraception - Pipeline by Luye Pharma Group Ltd, H2 2019
Female Contraception - Pipeline by MedinCell SA, H2 2019
Female Contraception - Pipeline by Micron Biomedical Inc, H2 2019
Female Contraception - Pipeline by Mithra Pharmaceuticals SA, H2 2019
Female Contraception - Pipeline by Mucommune LLC, H2 2019
Female Contraception - Pipeline by Orbis Biosciences Inc, H2 2019
Female Contraception - Pipeline by Orion Biotechnology Canada Ltd, H2 2019
Female Contraception - Pipeline by Ovastasis LLC, H2 2019
Female Contraception - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2019
Female Contraception - Pipeline by Viramal Ltd, H2 2019
Female Contraception - Pipeline by Yaso Therapeutics Inc, H2 2019
Female Contraception - Pipeline by YourChoice Therapeutics Inc, H2 2019
Female Contraception - Dormant Projects, H2 2019
Female Contraception - Dormant Projects, H2 2019 (Contd..1), H2 2019
Female Contraception - Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development for Female Contraception, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Agile Therapeutics Inc
Evestra Inc
Evofem Biosciences Inc
Exeltis Pharmaceuticals Holding SL
Hervana Ltd
Hydra Biosciences Inc
Luye Pharma Group Ltd
MedinCell SA
Micron Biomedical Inc
Mithra Pharmaceuticals SA
Mucommune LLC
Orbis Biosciences Inc
Orion Biotechnology Canada Ltd
Ovastasis LLC
Teva Pharmaceutical Industries Ltd
Number of Products under Development for Female Contraception, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Agile Therapeutics Inc
Evestra Inc
Evofem Biosciences Inc
Exeltis Pharmaceuticals Holding SL
Hervana Ltd
Hydra Biosciences Inc
Luye Pharma Group Ltd
MedinCell SA
Micron Biomedical Inc
Mithra Pharmaceuticals SA
Mucommune LLC
Orbis Biosciences Inc
Orion Biotechnology Canada Ltd
Ovastasis LLC
Teva Pharmaceutical Industries Ltd
